Biotech Showcase™ 2017: Payer environment will impact biopharma prospects in 2017

January 26, 2017

An increased focus on the need to access and develop truly transformational medicines was a key theme in the hallway chatter at this year’s Biotech Showcase/JP Morgan Healthcare meetings. Michael Hay, head of Informa Pharma Intelligence Products, shares with Mike Ward, global director of content at Informa Pharma Intelligence’s insights portfolio, his thoughts on how shareholder pressure for genuine patient benefits has implications for the pharma and biotech industries.

 

 


Meet Covance at BIO-Europe Spring® taking place in Barcelona, Spain, March 20–22, 2017. Find out how you can be a part of our event

Previous Article
Digital Health: Smart Devices Were Just The Beginning
Digital Health: Smart Devices Were Just The Beginning

The connectivity that will be created by the convergence of computers and health will truly alter the way k...

Next Article
Unmet needs, uncommon commitment: The shift toward investment in rare diseases
Unmet needs, uncommon commitment: The shift toward investment in rare diseases

Join biotech leaders, emerging innovators, investors and patient advocacy group reps for a candid, interact...